Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levothyroxine for NAFLD and Diabetes Control
NCT03281083Phase 2Terminated
- Sponsor
- Duke-NUS Medical School
- Start
- Mar 2014
- Primary completion
- Jul 2016
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of levothyroxine sodium in non-alcoholic fatty liver disease (NAFLD), sponsored by Duke-NUS Medical School. Primary endpoint: Absolute change in liver fat content at 16 weeks. Started Mar 2014; status: terminated.
02
Drugs
levothyroxine sodium
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03281083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03281083.